Cellex Cell Professionals Achieves Major Milestone in ATMP Manufacturing

On October 6, 2026, Cellex Cell Professionals announced a significant milestone, having surpassed 10,000 autologous ATMP manufacturing batches. This achievement marks their extensive experience as a contract development and manufacturing organization (CDMO) in personalized cell therapies. Each batch is uniquely produced for individual patients, involving tightly controlled processes like collection, manufacturing, and logistics.

This milestone is underpinned by Cellex's insight from its CAR-T programs and the challenges faced in developing autologous and CRISPR/Cas-edited allogeneic CAR-T therapies. The company continues to refine its processes to overcome scientific and regulatory hurdles, ensuring high-quality patient-specific operations.

Cellex is further expanding capabilities by adding Grade B cleanrooms at its Cologne Ossendorf site, aiming to support more complex cell therapy programs and deliver reliable therapies at scale, partnering with clinical and commercial entities for innovative healthcare solutions.